# Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

> **NCT00396656** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 30 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Atenolol
- **DRUG:** Hydrochlorothiazide (HCTZ))
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT00396656
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396656, "Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00396656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*